Pharmaceutical Regulation
3 articles on Pharmaceutical Regulation, written by Shotlee and medically reviewed for clinical accuracy.
Ozempic, Mounjaro & Compounded GLP-1s: South Africa's Regulatory Crackdown
South Africa's regulatory bodies are taking decisive action against the booming market for compounded GLP-1 weight-loss drugs, including versions of Ozempic and Mounjaro. This crackdown highlights significant safety concerns and potential risks to public health.
8 min read
FDA's GLP-1 Compounding Crackdown: What Patients Need to Know
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
7 min read
The GLP-1 Transformation: Aesthetic Medicine And The Impending Struggle For Dominance
GLP-1 medications have evolved beyond endocrinology to influence medical aesthetics, creating a hybrid market where pharmaceuticals meet consumer identity. This shift highlights opportunities in MedSpas and compounding pharmacies but also poses significant risks. Manufacturers must adapt to maintain control in this evolving landscape.
5 min read